

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that, with effect from March 15, 2021, Dr. Johannes NIPPGEN (“**Dr. Nippgen**”) has been appointed as our chief medical officer, who will be primarily responsible for the clinical development and transitional research of the Company’s innovative product pipelines, as well as participate in designing research and development strategy of innovative products and promote international cooperation; and, with effect from March 30, 2021, Mr. XU Weihao (徐偉豪) (“**Mr. Xu**”) has been appointed as our chief financial officer, who will be primarily responsible for the formulation of the Company’s financial and capital market strategy and investor relations matters, as well as participate in the Company’s international business expansion and cooperation.

The biographical details of Dr. Nippgen and Mr. Xu are set out below:

Dr. Nippgen has over 25 years of experience in medical industry. His industry expertise covers the clinical research and development and as well as project management in various international biopharma and biotech companies. From 2018 to 2021, he served as head of research and development in China at Merck Group. Prior to that, he served as a leader of research and development program at Merck KGaA (OTCMKTS: MKGAF), Karyopharm Therapeutics Inc. (NASDAQ ticker symbol: KPTI), and Glycotope GmbH, a wholly-owned subsidiary of Eli Lilly and Company. From 1994 to 2004, he worked at Universitätsklinikum Carl Gustav Carus, primarily responsible for surgical oncology and urology. Dr. Nippgen obtained his doctorate degree in clinical medicine from University of Mainz in German, and his another doctorate degree from University of Würzburg in German. He published in various regional and international journals including the New England Journal of Medicine.

Mr. Xu has more than ten years of experience in global capital markets, equity investment and financial management. Mr. Xu held executive roles in several companies listed in the United States and global investment companies. Prior to joining our Company, Mr. Xu served as the chief financial officer at CASI Pharmaceuticals Inc. (NASDAQ ticker symbol: CASI). He also served as the chief financial officer for 111, Inc. (NASDAQ ticker symbol: YI). In the area of investment, Mr. Xu served as a Portfolio Manager in Matthews International and worked in several other international funds. Mr. Xu received a master degree in finance and accounting from Columbia Business School.

The Board would like to express its warmest welcome to Dr. Nippgen and Mr. Xu .

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, March 30, 2021

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.